Search Clinical Trials

ABI-009 in Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors

The purpose of this study is to determine whether ABI-009 will make advanced, malignant neuroendocrine tumor(s) of the lung, gastrointestinal tract and/or pancreas that cannot…

Study of LOXO-292 in Advanced Solid Tumors, RET Fusion+ Solid Tumors, and Medullary Thyroid Cancer

This is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of LOXO-292 administered orally to…

Phase 1/2 Study of LOXO-195 in Patients with Previously Treated NTRK Fusion Cancers

This is a Phase 1/2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients age ≥ 1…

CT Perfusion in Predicting Outcomes in Ovarian Cancer Receiving Bevacizumab

This phase II trial studies how well computed tomography perfusion imaging works in predicting outcomes in patients with ovarian, fallopian tube, or primary peritoneal cancer…

Axitinib and Nivolumab in Treating Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma

This phase II trial studies how well axitinib and nivolumab works in treating participants with TFE/translocation renal cell carcinoma that cannot be removed by surgery…

Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Germ Cell Tumors

This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ…

Pacritinib for PMF, PPV-MF, or PET-MF Previously Treated with Ruxolitinib

The study is designed to support a Pacritinib dosage selection decision. 3 dosages will be evaluated, with patients randomized 1:1:1 to Pacritinib 100 mg QD,…

Olaparib, Cediranib, and Wee1 Inhibitor for Recurrent, Refractory, or Metastatic Endometrial Cancer

This randomized phase II trial studies how well Olaparib, Cediranib maleate, and Wee1 Inhibitor, AZD1775, work in treating patients with endometrial cancer that has come…

KEYNOTE-224: Pembrolizumab as Monotherapy for Advanced Hepatocellular Carcinoma

This is an efficacy and safety study of Pembrolizumab (KEYTRUDA®) as monotherapy in participants with HCC in 2 cohorts: participants with advanced HCC and with…

HIMALAYA: Durvalumab + Tremelimumab as 1st-line Treatment for Unresectable Hepatocellular Carcinoma

This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of Durvalumab plus Tremelimumab combination therapy and Durvalumab monotherapy…